Global Transthyretin Amyloidosis Treatment Market Size is valued at USD 5.5 Bn in 2024 and is predicted to reach USD 11.7 Bn by the year 2034 at a 8.0% CAGR during the forecast period for 2025-2034.
Transthyretin amyloidosis (ATTR) is an uncommon and progressive condition resulting from the misfolding of transthyretin (TTR) proteins, which leads to amyloid accumulation in organs and tissues, mostly impacting the heart and nervous system.
Patients undergoing transthyretin amyloidosis treatment are expected to be driven by the rising elderly patient demographic and the growing prevalence of transthyretin amyloidosis among these patients. According to a 2022 study published in the European Journal of Heart Failure, patients aged 70 years and older were found to have transthyretin amyloidosis (ATTR).
Furthermore, the ageing population is driving the industry, especially in developed nations, as the condition is more prevalent in older people. For instance, transthyretin amyloidosis (ATTRwt) of the wild-type primarily affects older males; postmortem reports indicate that transthyretin amyloid cardiac deposits are present in 25% of patients over the age of 80. Therefore, it is anticipated that the incidence rates of transthyretin amyloidosis illness will rise in tandem with the worldwide elderly population, driving the transthyretin amyloidosis treatment market expansion.
The transthyretin amyloidosis treatment market is segmented based on type, therapy, disease type, and distribution channel. Based on type, the market is segmented into ATTR-PN and ATTR-CM. By therapy, the market is divided into Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, and Pipeline Therapy. By disease type, the market is segmented into Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) and Wild Type Amyloidosis. The distribution channel segment includes Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies.
The ATTR-CM category is expected to hold a major global market share in 2023. This is caused by the high frequency of disease and the rapid improvement in diagnostic rates. Although the precise frequency of the condition is unknown, different autopsy reports indicate that between 22% and 25% of individuals 80 years of age and older had heart TTR amyloid accumulation. Even yet, patients with ATTR-CM amyloidosis typically have modest amyloid deposition. Additionally, the introduction of new medications to treat ATTR-CM is anticipated to accelerate the growth of the transthyretin amyloidosis treatment market. For instance, the U.S. FDA approved Pfizer Inc.'s VYNDAQEL and VYNDAMAX in May 2019 for the treatment of ATTR-CM.
The majority of hospitals focus on the diagnosis, investigation, and treatment of the illness. For instance, the goal of Massachusetts-based Brigham and Women's Hospital is to identify and treat diseases that have been misdiagnosed. It launched the Amyloidosis Program, providing patient-centred care, access to cutting-edge treatments, and new clinical trials. The group of professionals would raise awareness among patients and educate doctors and patients. These programs would help the transthyretin amyloidosis treatment market expand even further.
The North American transthyretin amyloidosis treatment market is expected to note the highest market share in revenue in the near future. Strong reimbursement rules, a well-established healthcare infrastructure, and a high level of patient and healthcare professional knowledge regarding rare diseases are among the region's many strengths. The industry's expansion in North America is further aided by the existence of significant market participants and continuous research and development initiatives. Furthermore, the region's early adoption of cutting-edge medicines and a strong focus on innovation have increased its market share in transthyretin amyloidosis treatment. In addition, the Middle East and Africa are projected to grow rapidly in the global transthyretin amyloidosis treatment market. The high unmet treatment demands, increasing approval rates, and rising ailment prevalence are expected to boost the transthyretin amyloidosis treatment market in the following years. Some important factors that are expected to be the key drivers of growth are a large target population, sensible healthcare reforms, and an increase in the awareness of illnesses.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 5.5 Bn |
| Revenue Forecast In 2034 | USD 9.4 Bn |
| Growth Rate CAGR | CAGR of 8.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Therapy, Disease Type, And Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Ionis Pharmaceuticals, Inc., Pfizer Inc., AstraZeneca, Johnson & Johnson Services, Inc., Alnylam Pharmaceuticals, Inc., Astellas Pharma, Inc.. BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, Prothena, SOM Biotech, and Others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Transthyretin Amyloidosis Treatment Market By Type-
Transthyretin Amyloidosis Treatment Market By Therapy-
Transthyretin Amyloidosis Treatment Market By Disease Type-
Transthyretin Amyloidosis Treatment Market By Distribution Channel-
Transthyretin Amyloidosis Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Transthyretin Amyloidosis Treatment Market Snapshot
Chapter 4. Global Transthyretin Amyloidosis Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034
4.8. Global Transthyretin Amyloidosis Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Transthyretin Amyloidosis Treatment Industry Trends
Chapter 5. Transthyretin Amyloidosis Treatment Market Segmentation 1: By Therapy, Estimates & Trend Analysis
5.1. Market Share by Therapy, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy:
5.2.1. Targeted Therapy
5.2.1.1. Onpattro
5.2.1.2. Inotersen
5.2.1.3. Vyndaqel/Vyndamax
5.2.2. Supportive Therapy
5.2.3. Pipeline Therapy
Chapter 6. Transthyretin Amyloidosis Treatment Market Segmentation 2: By Type, Estimates & Trend Analysis
6.1. Market Share by Type, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Types:
6.2.1. ATTR-PN
6.2.2. ATTR-CM
Chapter 7. Transthyretin Amyloidosis Treatment Market Segmentation 3: By Disease Type, Estimates & Trend Analysis
7.1. Market Share by Disease Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Disease Types:
7.2.1. Hereditary Transthyretin Amyloidosis
7.2.1.1. Polyneuropathy
7.2.1.2. Cardiomyopathy
7.2.1.3. Mixed Type
7.2.2. Wild Type Amyloidosis
Chapter 8. Transthyretin Amyloidosis Treatment Market Segmentation 4: By Distribution Channel Industry, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel Industry, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel Industrys:
8.2.1. Hospital Pharmacies
8.2.2. Specialty Pharmacies
8.2.3. Retail Pharmacies
8.2.4. Online Pharmacies
Chapter 9. Transthyretin Amyloidosis Treatment Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Transthyretin Amyloidosis Treatment Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
9.2.3. North America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.2.4. North America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2021-2034
9.2.5. North America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel Industry, 2021-2034
9.3. Europe
9.3.1. Europe Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
9.3.3. Europe Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.3.4. Europe Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2021-2034
9.3.5. Europe Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel Industry, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
9.4.3. Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.4.4. Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts By Disease Type, 2021-2034
9.4.5. Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel Industry, 2021-2034
9.5. Latin America
9.5.1. Latin America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
9.5.3. Latin America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.5.4. Latin America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2021-2034
9.5.5. Latin America Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel Industry, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
9.6.3. Middle East & Africa Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.6.4. Middle East & Africa Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2021-2034
9.6.5. Middle East & Africa Transthyretin Amyloidosis Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel Industry, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Pfizer Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerTherapyance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Johnson & Johnson Services, Inc.
10.2.3. Ionis Pharmaceuticals, Inc.
10.2.4. Alnylam Pharmaceuticals, Inc.
10.2.5. BridgeBio Pharma, Inc.
10.2.6. Bristol-Myers Squibb Company
10.2.7. Acrotech Biopharma
10.2.8. AstraZeneca
10.2.9. Astellas Pharma, Inc.
10.2.10. Prothena
10.2.11. SOM Biotech
10.2.12. Other Market Players
Transthyretin Amyloidosis Treatment Market By Type-
Transthyretin Amyloidosis Treatment Market By Therapy-
Transthyretin Amyloidosis Treatment Market By Disease Type-
Transthyretin Amyloidosis Treatment Market By Distribution Channel-
Transthyretin Amyloidosis Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-